JP Morgan Reiterates Buy Rating on Lexeo Therapeutics, Inc.
JP Morgan maintains its buy rating on Lexeo Therapeutics, Inc., setting a target price of $9, a 89.47% upside from the current price.
Key Points
- JP Morgan reiterated its buy rating on Lexeo Therapeutics, Inc. with a target price of $9 on June 25, 2026.
- JP Morgan's $9 price target implies 89.47% upside from Lexeo Therapeutics, Inc.'s ($LXEO) current $4.75 share price.
- Lexeo Therapeutics, Inc. (NasdaqGM: LXEO) shares traded near $4.89 on Thursday, with a 52-week range of $3.60 to $10.99.
- Insider activity includes multiple transactions by executives, with recent analyst ratings highlighting a strong buy consensus.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
JP Morgan reiterated its buy rating on Lexeo Therapeutics, Inc. (NasdaqGM: LXEO) on June 25, 2026. The financial firm set a target price of $9 for the biotechnology company, which focuses on genetic medicine. Shares of Lexeo traded near $4.89 on Thursday, reflecting investor interest in the company's potential.
JP Morgan vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Lexeo Therapeutics
Several institutional investors have made moves in Lexeo Therapeutics recently. Paradigm Biocapital Advisors LP increased its holdings by 1,420,936 shares, ending with 6,184,134 shares valued at about $35.5 million. BlackRock, Inc. added 203,308 shares, bringing its total to 5,110,871 shares worth approximately $29.3 million. Affinity Asset Advisors, LLC significantly boosted its stake by 1,850,211 shares, holding 5,050,211 shares valued at $28.9 million. Meanwhile, Janus Henderson Group PLC trimmed its position by 533,206 shares, leaving it with 4,976,429 shares worth about $28.5 million.
Lexeo Therapeutics, Inc. Stock Down 2.3%
On Thursday, shares of Lexeo Therapeutics, Inc. (NasdaqGM: LXEO) traded near $4.89. The company has a market cap of approximately $395.7 million. Lexeo's stock has a 52-week low of $3.60 and a high of $10.99, with a 50-day moving average of $5.43 and a 200-day moving average of $7.15. The company is not currently profitable, resulting in no meaningful forward P/E ratio. Lexeo's beta is 1.389, indicating some volatility compared to the market.
$LXEO price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Lexeo Therapeutics, Inc.
Recent insider activity at Lexeo Therapeutics includes several transactions. On May 18, 2026, Chief Operating Officer Jose Manuel Otero sold 1,302 shares at an average price of $5.07. On the same day, CEO Richard Nolan Townsend sold 3,342 shares at $5.06. Earlier, on April 6, 2026, Townsend sold 55,000 shares at $5.69 under a planned transaction. Conversely, on March 13, 2026, Townsend purchased 2,623 shares at $2.64, while Otero bought 5,930 shares at the same price.
Analysts Set New Price Targets
On June 25, 2026, JP Morgan maintained its buy rating for Lexeo Therapeutics with a $9 target price. Earlier, on May 11, 2026, Chardan Capital also maintained a buy rating with a $17 target. HC Wainwright & Co. and Raymond James have also shown positive outlooks, with targets of $10 and $25, respectively. The consensus among analysts is a strong buy, with a mean target price of $20.9 from ten opinions.
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. is a biotechnology company based in New York, New York. It focuses on developing genetic medicine for hereditary and acquired diseases with high unmet needs. The company has a robust pipeline, including candidates for conditions like Friedreich ataxia cardiomyopathy and Alzheimer's disease. Founded in 2017, Lexeo employs about 59 people and is led by CEO Mr. R. Nolan Townsend.
Bottom Line
JP Morgan's reiterated buy rating and $9 target reflect confidence in Lexeo Therapeutics' potential in genetic medicine. Investors are watching the company's progress closely, especially given its focus on high-need areas like cardiomyopathy and Alzheimer's. As with all 13F filings and analyst reports, remember these insights are backward-looking and may not represent current positions or future performance.
Get Lexeo Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $LXEO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.